[go: up one dir, main page]

PE20170907A1 - Compuestos neuroactivos y metodos de uso de los mismos - Google Patents

Compuestos neuroactivos y metodos de uso de los mismos

Info

Publication number
PE20170907A1
PE20170907A1 PE2017000579A PE2017000579A PE20170907A1 PE 20170907 A1 PE20170907 A1 PE 20170907A1 PE 2017000579 A PE2017000579 A PE 2017000579A PE 2017000579 A PE2017000579 A PE 2017000579A PE 20170907 A1 PE20170907 A1 PE 20170907A1
Authority
PE
Peru
Prior art keywords
methods
bitopertin
refers
neuroactive compounds
sterol
Prior art date
Application number
PE2017000579A
Other languages
English (en)
Inventor
Michael C Quirk
James J Doherty
Botella Gabriel Martinez
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of PE20170907A1 publication Critical patent/PE20170907A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN METODO DE TRATAMIENTO DE UN TRASTORNO DE SINTESIS DE ESTEROL O UN TRASTORNO DE DEFICIENCIA DE ESTEROL, EL CUAL COMPRENDE ADMINISTRAR AL SUJETO UNA CANTIDAD EFECTIVA DE UN COMPUESTO QUE MODULA EL RECEPTOR NMDA TAL COMO BITOPERTIN (COMPUESTO DE FORMULA VI), COMPUESTOS DE FORMULA (i), (ii), ENTRE OTROS. TAMBIEN SE REFIERE A UNA FORMA DE DOSIFICACION QUE COMPRENDE EL MODULADOR DEL RECEPTOR NMDA
PE2017000579A 2014-10-07 2015-10-07 Compuestos neuroactivos y metodos de uso de los mismos PE20170907A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462060932P 2014-10-07 2014-10-07

Publications (1)

Publication Number Publication Date
PE20170907A1 true PE20170907A1 (es) 2017-07-12

Family

ID=55653736

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000579A PE20170907A1 (es) 2014-10-07 2015-10-07 Compuestos neuroactivos y metodos de uso de los mismos

Country Status (17)

Country Link
US (2) US20170304321A1 (es)
EP (1) EP3204011A4 (es)
JP (3) JP2017530982A (es)
KR (1) KR20170065637A (es)
CN (2) CN112121171A (es)
AU (2) AU2015330906A1 (es)
BR (1) BR112017007053A2 (es)
CA (1) CA2963938C (es)
IL (2) IL292465B2 (es)
MX (2) MX388694B (es)
MY (1) MY202135A (es)
PE (1) PE20170907A1 (es)
PH (1) PH12017500639A1 (es)
RU (1) RU2764702C2 (es)
SG (2) SG11201702799UA (es)
WO (1) WO2016057713A1 (es)
ZA (1) ZA201702545B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012304412A1 (en) 2011-09-08 2014-03-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
DK3461834T3 (da) 2013-03-13 2021-08-23 Sage Therapeutics Inc Neuroaktive steroider
ES2852054T3 (es) 2013-03-15 2021-09-10 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
MX2021011641A (es) 2013-12-24 2023-03-10 Durect Corp Usos de sulfatos de colesterol oxigenados (soc).
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
MA54851A (fr) 2015-07-06 2021-12-08 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
HRP20210526T8 (hr) 2015-07-06 2021-08-20 Sage Therapeutics, Inc. Oksisteroli i postupci za njihovu uporabu
HK1255500A1 (zh) 2015-07-06 2019-08-16 Sage Therapeutics, Inc. 氧固醇及其使用方法
LT3436022T (lt) 2016-04-01 2022-06-27 Sage Therapeutics, Inc. Oksisteroliai ir jų panaudojimo būdai
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MD3481846T2 (ro) 2016-07-07 2021-11-30 Sage Therapeutics Inc 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
HUE059768T2 (hu) * 2016-08-02 2022-12-28 Univ Virginia Commonwealth 5-kolesztén-3,25-diol, 3-szulfátot (25HC3S) vagy annak gyógyszerészetileg elfogadható sóját és legalább egy ciklikus oligoszacharidot tartalmazó készítmények
ES2935057T3 (es) * 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
TWI772331B (zh) 2016-10-18 2022-08-01 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
IL297804A (en) * 2016-10-18 2022-12-01 Sage Therapeutics Inc Oxysterols and methods of using them
EP3335730A1 (en) * 2016-12-15 2018-06-20 Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) Compounds for treating x-linked adrenoleukodystrophy
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO2006037016A2 (en) * 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
GB0712494D0 (en) * 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009059961A2 (en) * 2007-11-06 2009-05-14 N.V. Organon A method of hormone suppression in humans
SG195568A1 (en) * 2008-05-09 2013-12-30 Univ Emory Nmda receptor antagonists for the treatment of neuropsychiatric disorders
WO2010065709A2 (en) * 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010088414A2 (en) * 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
WO2011028794A2 (en) * 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
AU2012304412A1 (en) * 2011-09-08 2014-03-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP2841067A4 (en) * 2012-04-25 2016-04-13 Univ California MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME
WO2014025942A1 (en) * 2012-08-09 2014-02-13 Emory University Nmda receptor modulators and uses related thereto
KR20150110787A (ko) * 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
DK3461834T3 (da) 2013-03-13 2021-08-23 Sage Therapeutics Inc Neuroaktive steroider
MX2015012437A (es) * 2013-03-13 2016-04-15 Sage Therapeutics Inc Esteroides neuroactivos, composiciones, y usos de los mismos.
JP6628745B2 (ja) * 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
EP3166613A4 (en) * 2014-07-09 2018-02-21 Duke University Compositions and methods for the repair of myelin
HK1255500A1 (zh) * 2015-07-06 2019-08-16 Sage Therapeutics, Inc. 氧固醇及其使用方法

Also Published As

Publication number Publication date
ZA201702545B (en) 2019-06-26
JP2020196759A (ja) 2020-12-10
EP3204011A1 (en) 2017-08-16
CA2963938C (en) 2023-10-24
US20230218638A1 (en) 2023-07-13
IL292465A (en) 2022-06-01
KR20170065637A (ko) 2017-06-13
RU2017115849A (ru) 2018-11-13
CN112121171A (zh) 2020-12-25
PH12017500639A1 (en) 2017-09-25
EP3204011A4 (en) 2018-06-20
JP2022033285A (ja) 2022-02-28
IL292465B2 (en) 2025-06-01
AU2021200721A1 (en) 2021-03-04
WO2016057713A1 (en) 2016-04-14
SG10202011773UA (en) 2021-01-28
IL251505A0 (en) 2017-05-29
JP2017530982A (ja) 2017-10-19
AU2015330906A1 (en) 2017-04-27
CA2963938A1 (en) 2016-04-14
SG11201702799UA (en) 2017-05-30
RU2017115849A3 (es) 2019-05-15
AU2021200721B2 (en) 2023-06-01
IL292465B1 (en) 2025-02-01
RU2764702C2 (ru) 2022-01-19
MY202135A (en) 2024-04-05
MX2021011939A (es) 2021-11-03
BR112017007053A2 (pt) 2018-06-19
US20170304321A1 (en) 2017-10-26
CN107405352A (zh) 2017-11-28
MX2017004684A (es) 2017-06-30
IL251505B (en) 2022-05-01
NZ730862A (en) 2024-01-26
MX388694B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
PE20170907A1 (es) Compuestos neuroactivos y metodos de uso de los mismos
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
PH12018501096A1 (en) Modulators of chemokine receptors
CL2015003491A1 (es) Compuestos químicos.
UY36076A (es) Compuestos útiles como inhibidores de la interacción proteínaproteína pd-1/pd-l1 y cd80/pd-l1, y composiciones farmacéuticas que los contienen.
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CL2017000054A1 (es) Indoles funcionalizados y sustituidos como agentes anti-cáncer
NZ710444A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
GT201700062A (es) N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b
EA201992183A3 (ru) Синтез полициклических карбамоилпиридоновых соединений
NI201900075A (es) Compuesto moduladores del receptor de hidrocarburos de arilo (ahr)
PE20230683A1 (es) Moduladores de receptor nuclear
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
GT201700194A (es) Formulación de combinación de tesofensina y betabloqueante
EA201790884A1 (ru) 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
EA201790496A1 (ru) Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
ECSP16074207A (es) Pirazinas moduladoras de gpr6
EA026371B8 (ru) Индолкарбонитрилы в качестве модуляторов рецептора андрогенов
MX2016011535A (es) Ureas asimetricas p-sustituidas y usos medicos de las mismas.
MX2016015631A (es) Nuevos compuestos.
MX2016016612A (es) Formulaciones estables de undecanoato de testosterona.
MX2016015298A (es) Inhibidores de nampt y metodos.
MX2017009514A (es) Moduladores de los receptores a3 de adenosina.